BTC secures exclusive ANZ distribution rights for Sativex

Summary by 6ix AI

BTC Health Ltd has announced that its subsidiary, BTC Pharma, has secured exclusive distribution rights for Sativex in Australia and New Zealand through an agreement with CNX Therapeutics. Sativex is a prescription medicine used for treating moderate to severe spasticity due to multiple sclerosis and is one of the few medicinal cannabis products registered in Australia. BTC Pharma will manage all regulatory and commercial activities related to Sativex in both countries, aiming to enhance engagement with healthcare professionals and patients. The agreement has an initial term of five years, with potential for extension, and is expected to generate significant sales growth over time.

Written by 6ix AI from the company’s filing. How 6ix writes summaries